CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 370 enrolled
Drug / intervention
Aricept® Evessdrug
Likely dose
Aricept® Evess 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00889603
NCT00889603N/ACompleted
CompareCT.gov

Non-Interventional Study With Aricept® Evess In Patients Diagnosed With Mild And Moderate Alzheimer's Disease Or Vascular Dementia

Pfizer·observational·Posted Apr 29, 2009·Updated Mar 31, 2011

In Brief

An observational study evaluating Aricept® Evess for Alzheimer's Disease and Vascular Dementia. Completed, enrolled 370 participants across 12 sites.

Detailed Summary

The Aricept® Evess study is a prospective, non-comparative, non-interventional study on use of Aricept® Evess in the treatment of out-patients with AD and Vascular Dementia. The 24 week length of the study aims to collect data from a large number of patients (n= 400) on the safety and efficacy at the usual dosage of the product providing an overview of Aricept® Evess profile.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Vascular Dementia
CountriesRomania
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2009
Enrollment StartMay 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.2 years ago

Interventions

Aricept® Evessdrug

5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets. Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing).